Abstract
BackgroundNeutrophil gelatinase-associated lipocalin (NGAL) has been identified as an early biomarker for prediction of acute kidney injury (AKI). However, the utility of NGAL to predict the occurrence of AKI in septic patients remains controversial. We performed a systematic review and meta-analysis to evaluate the evidence on diagnosis of sepsis AKI and the prediction of other clinical outcomes.MethodThe MEDLINE, EMBASE, Cochrane Library, Wanfang, and CNKI databases were systematically searched up to August 19, 2015. Quality assessment was applied by using the Quality Assessment for Studies of Diagnostic Accuracy (QUADAS-2) tool. The diagnostic performance of NGAL for the prediction of AKI in sepsis was evaluated using pooled estimates of sensitivity, specificity, likelihood ratio, and diagnostic odds ratio (DOR), as well as summary receiver operating characteristic curves (SROC).ResultsFifteen studies with a total of 1,478 patients were included in the meta-analysis. For plasma NGAL, the pooled sensitivity and specificity with corresponding 95 % confidence intervals (CI) were 0.83 (95 % CI: 0.77 − 0.88) and 0.57 (95 % CI: 0.54 − 0.61), respectively. The pooled positive likelihood ratio (PLR) was 3.10 (95 % CI: 1.57 − 6.11) and the pooled negative likelihood ratio (NLR) was 0.24 (95 % CI: 0.13 − 0.43). The pooled DOR was 14.72 (95 % CI: 6.55 − 33.10) using a random effects model. The area under the curve (AUC) for SROC to summarize diagnostic accuracy was 0.86. For urine NGAL, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC values were 0.80 (95 % CI: 0.77 − 0.83), 0.80 (95 % CI: 0.77 − 0.83), 4.42 (95 % CI: 2.84 − 6.89), 0.21 (95 % CI: 0.13 − 0.35), 24.20 (95 % CI: 9.92 − 59.05) and 0.90, respectively. Significant heterogeneity was explored as a potential source. There was no notable publication bias observed across the eligible studies. NGAL for prediction of renal replacement therapy (RRT) and mortality associated with AKI in septic patients were also evaluated.ConclusionTo a certain extent, NGAL is not only an effective predictive factor for AKI in the process of sepsis, but also shows potential predictive value for RRT and mortality. However, future trials are needed to clarify this controversial issue.
Highlights
Neutrophil gelatinase-associated lipocalin (NGAL) has been identified as an early biomarker for prediction of acute kidney injury (AKI)
NGAL for prediction of renal replacement therapy (RRT) and mortality associated with AKI in septic patients were evaluated
We systematically reviewed studies on the diagnostic accuracy of plasma and urine NGAL for prediction of AKI in septic patients
Summary
Neutrophil gelatinase-associated lipocalin (NGAL) has been identified as an early biomarker for prediction of acute kidney injury (AKI). We performed a systematic review and meta-analysis to evaluate the evidence on diagnosis of sepsis AKI and the prediction of other clinical outcomes. Along with the deepening understanding, similar studies have gradually increased the accuracy of prediction of sepsis-induced AKI. It remains controversial whether NGAL is a predictive biomarker of early AKI in septic patients because of the lack of corresponding statistical data. In view of this confusion, we performed a systematic review and meta-analysis to evaluate the evidence on diagnosis of sepsis AKI to predict clinical outcomes of renal replacement therapy (RRT) and mortality
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.